ISCHAEMIA-MODIFIED ALBUMINM MEASURED AS A BIOMARKER IN EARLY DIAGNOSIS OF THE ACUTE CORONARY SYNDROME
Saker, M., Elhefnawy, K., El Sayed, M., Fawzy, M. (2014). ISCHAEMIA-MODIFIED ALBUMINM MEASURED AS A BIOMARKER IN EARLY DIAGNOSIS OF THE ACUTE CORONARY SYNDROME. EKB Journal Management System, 20(5), 1-9. doi: 10.21608/zumj.2014.4435
Mohamed Saker; Khaled Elhefnawy; Mohamed El Sayed; Mohamed Fawzy. "ISCHAEMIA-MODIFIED ALBUMINM MEASURED AS A BIOMARKER IN EARLY DIAGNOSIS OF THE ACUTE CORONARY SYNDROME". EKB Journal Management System, 20, 5, 2014, 1-9. doi: 10.21608/zumj.2014.4435
Saker, M., Elhefnawy, K., El Sayed, M., Fawzy, M. (2014). 'ISCHAEMIA-MODIFIED ALBUMINM MEASURED AS A BIOMARKER IN EARLY DIAGNOSIS OF THE ACUTE CORONARY SYNDROME', EKB Journal Management System, 20(5), pp. 1-9. doi: 10.21608/zumj.2014.4435
Saker, M., Elhefnawy, K., El Sayed, M., Fawzy, M. ISCHAEMIA-MODIFIED ALBUMINM MEASURED AS A BIOMARKER IN EARLY DIAGNOSIS OF THE ACUTE CORONARY SYNDROME. EKB Journal Management System, 2014; 20(5): 1-9. doi: 10.21608/zumj.2014.4435

ISCHAEMIA-MODIFIED ALBUMINM MEASURED AS A BIOMARKER IN EARLY DIAGNOSIS OF THE ACUTE CORONARY SYNDROME

Zagazig University Medical Journal
Article 12, Volume 20, Issue 5, September 2014, Page 1-9  XML PDF (549.54 K)
Document Type: Original Article
DOI: 10.21608/zumj.2014.4435
View on SCiNiTO View on SCiNiTO
Authors
Mohamed Saker1; Khaled Elhefnawy2; Mohamed El Sayed2; Mohamed Fawzy3
1Internal medicine departments, Faculty of Medicine, Zagazig University.
2Internal medicine departments, Faculty of Medicine, Zagazig University.
3Medical Biochemistry departments, Faculty of Medicine, Zagazig University.
Abstract
BACKGROUND: An early identification of the patients with the Acute Coronary Syndrome (ACS) is of prime importance, due to the associated very high mortality. Only about 22% of the patients, who present at the emergency cardiology care centers with chest pain, have coronary disease. Ischemia modified albumin (IMA) is emerging as an exciting early marker of myocardial ischemia for diagnostic use in patients with suspected acute coronary syndrome (ACS). During an ischemic event, IMA concentrations in blood rise quickly above normal levels and remain elevated, returning to normal levels several hours after cessation of ischemia. IMA has recently been shown to be an early and sensitive marker of myocardial Ischemia. OBJECTIVE: The current study was to validate IMA or Albumin Cobalt Binding (ACB) assay when used together with standard markers of myocardial necrosis for the diagnosis and early detection of patients with ACS. METHODS: We enrolled 45 patients admitted to intensive cardiac care unit (ICCU) within 6 hours having acute chest pain and 15 healthy age and sex matched volunteers who didn't have any evidence of coronary artery disease to form the control group. The serum IMA level was estimated by the albumin cobalt binding test by using a digital spectrophotometer. At presentation serum IMA in conjunction with electrocardiogram (ECG) and cardiac enzymes Troponin I (cTnI) and CK-MB were evaluated. RESULTS: IMA levels were significantly higher in ischaemic patients compared to healthy controls. The sensitivity of IMA to detect ischaemia was 83.4% when IMA was combined with cTnI and CKMB, the sensitivity increased to 93%. CONCLUSIONS: IMA has been found to be a highly sensitive, early diagnostic marker of acute chest pain and earlier rule out test in ACS patients. The combined use of IMA and cardiac troponin I enhances the sensitivity and specificity. Hence, a combination of IMA and cardiac troponin I can be used as a more precise diagnostic marker for ACS.
Keywords
Acute coronary syndrome (ACS); Cardiac ischemia; Cardiac biomarkers; Ischemia modified albumin (IMA)
Statistics
Article View: 164
PDF Download: 279